Targeting a weakness in aggressive prostate cancer linked to Rb1 and p53 genes
Dissecting and targeting a novel vulnerability in aggressive Rb1 and p53 doubly deficient prostate cancer
['FUNDING_R01'] · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · NIH-10892019
This study is looking at a type of prostate cancer that doesn't have two important genes, Rb1 and p53, to see how this affects the cancer's growth, and it's exploring whether a protein called GRK3, which is more common in aggressive cases, can be targeted to help develop new treatments.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-10892019 on ClinicalTrials.gov |
What this research studies
This research investigates a specific vulnerability in prostate cancer that lacks both Rb1 and p53 tumor suppressor genes. By understanding how these deficiencies contribute to cancer progression, the study aims to identify new treatment strategies. The researchers are focusing on a protein called GRK3, which is found at higher levels in aggressive prostate cancer cases. They will use genetic and pharmacological methods to explore how targeting GRK3 can affect cancer cell survival and progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with aggressive prostate cancer that shows deficiencies in Rb1 and p53 genes.
Not a fit: Patients with prostate cancer that does not involve Rb1 and p53 deficiencies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for aggressive prostate cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results in targeting similar vulnerabilities in cancer cells, suggesting potential for success in this approach.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LI, WENLIANG — UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
- Study coordinator: LI, WENLIANG
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Patient